97 related articles for article (PubMed ID: 30890422)
1. Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.
Vinagre I; Gerstein H; Viñals C; Conget I
Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):467-468. PubMed ID: 30890422
[No Abstract] [Full Text] [Related]
2. [Dulaglutide and liraglutide compared].
Bruhn C
Med Monatsschr Pharm; 2015 May; 38(5):198-9. PubMed ID: 26364414
[No Abstract] [Full Text] [Related]
3. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Boye KS; Riddle MC; Gerstein HC; Mody R; Garcia-Perez LE; Karanikas CA; Lage MJ; Riesmeyer JS; Lakshmanan MC
Diabetes Obes Metab; 2019 Jun; 21(6):1299-1304. PubMed ID: 30714309
[TBL] [Abstract][Full Text] [Related]
4. Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report.
Fukuda G; Yoshida T; Hirayama A; Umezawa Y; Takemoto M
Geriatr Gerontol Int; 2019 Dec; 19(12):1289-1290. PubMed ID: 31823494
[No Abstract] [Full Text] [Related]
5. Two new GLP-1 receptor agonists for diabetes.
Med Lett Drugs Ther; 2014 Nov; 56(1455):109-11. PubMed ID: 25372847
[No Abstract] [Full Text] [Related]
6. Drug-Induced Liver Injury Due to Dulaglutide Use.
Patel AV; Jotwani PM; Lee TP
Am J Ther; 2019; 26(5):e620-e622. PubMed ID: 30870146
[No Abstract] [Full Text] [Related]
7. [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes].
Scheen AJ
Rev Med Liege; 2016 Mar; 71(3):154-60. PubMed ID: 27311248
[TBL] [Abstract][Full Text] [Related]
8. New drugs: dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate.
Hussar DA; Wetty DR
J Am Pharm Assoc (2003); 2015; 55(1):106, 108-10. PubMed ID: 25575154
[No Abstract] [Full Text] [Related]
9. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D
Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094
[TBL] [Abstract][Full Text] [Related]
10. Pyoderma gangrenosum associated with dulaglutide therapy.
Hamann CR; Chung C; Kaffenberger BH
Int J Dermatol; 2019 Oct; 58(10):1202-1204. PubMed ID: 30345551
[No Abstract] [Full Text] [Related]
11. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
[TBL] [Abstract][Full Text] [Related]
12. Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.
Matfin G; Van Brunt K; Zimmermann AG; Threlkeld R; Ignaut DA
J Diabetes Sci Technol; 2015 Apr; 9(5):1071-9. PubMed ID: 25901022
[TBL] [Abstract][Full Text] [Related]
13. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2016; 9(3):385-99. PubMed ID: 26761217
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme.
Yu M; Van Brunt K; Varnado OJ; Boye KS
Diabetes Obes Metab; 2016 Apr; 18(4):419-24. PubMed ID: 26691396
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Nauck MA; Frossard JL; Barkin JS; Anglin G; Hensley IE; Harper KD; Milicevic Z
Diabetes Care; 2017 May; 40(5):647-654. PubMed ID: 28283565
[TBL] [Abstract][Full Text] [Related]
16. Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.
Garg A; Kumar A
Curr Drug Saf; 2018; 13(3):165-170. PubMed ID: 29852875
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
18. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riesmeyer JS; Riddle MC; Rydén L; Xavier D; Atisso CM; Dyal L; Hall S; Rao-Melacini P; Wong G; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T;
Lancet; 2019 Jul; 394(10193):121-130. PubMed ID: 31189511
[TBL] [Abstract][Full Text] [Related]
19. Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan.
Onishi Y; Oura T; Matsui A; Matsuura J; Iwamoto N
Endocr J; 2017 May; 64(5):553-560. PubMed ID: 28367916
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]